Last updated: August 8, 2022
Sponsor: Queen's University
Overall Status: Active - Recruiting
Phase
2
Condition
Anxiety Disorders
Post-traumatic Stress Disorders
Panic Disorders
Treatment
N/AClinical Study ID
NCT04771767
14521759
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diagnosis of PTSD by a psychiatrist on the team using the Clinician Administered PTSDScale (CAPS-5) with a score of at least 50 and a medium presentation.
- Patients will have received at least 2 different types of prior treatment, both ofwhich produced less than a 50% reduction in the participant's symptoms.
- Participants with hypertension or cardiovascular disease must be receiving stabletreatment to participate.
- Participants must speak and read English, and will have consistent and reliable accessto the internet.
- Patients with suicidal ideation will be included.
- Patients with a history of substance abuse will be included (except for opioid usedisorder).
Exclusion
Exclusion Criteria: Hypomanic/manic episodes, bipolar disorder, acute psychosis, opioid use disorder, treatmentwith Naltrexone, pregnancy, postpartum, breastfeeding, untreated hypertension,cardiovascular disease, ASPD, active homicidal ideation, and general noncompliance with thestudy protocol.
Study Design
Total Participants: 16
Study Start date:
August 01, 2021
Estimated Completion Date:
March 31, 2024
Study Description
Connect with a study center
Queen's University
Kingston, Ontario K7L 3N6
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.